Physician profile
Arshad Ali
NPI 1508178526
$5,485.77
in general payments reported to CMS, 2019-2025
26 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.29 · 2020: $83.54 · 2021: $210 · 2022: $631 · 2023: $1,255 · 2024: $1,461 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,384.55 |
| Education | $165.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,418.80 | 2021-2025 | Farxiga |
| Amgen INC. | $606.58 | 2022-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $483.52 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $461.29 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $286.53 | 2021-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.39 | 2021-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $260.58 | 2022-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $256.06 | 2021-2025 | |
| Horizon Therapeutics Plc | $225.30 | 2020-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $194.20 | 2022-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $173.39 | 2024-2025 | |
| Ardelyx, INC. | $145.74 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $102.24 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Fresenius USA Marketing, INC. | $99.01 | 2021-2024 | Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $79.29 | 2022-2025 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $72.28 | 2021-2024 | Injectafer |
| Genzyme Corporation | $69.52 | 2024-2025 | |
| Scpharmaceuticals INC. | $65.06 | 2025 | |
| Akebia Therapeutics INC | $51.84 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $40.21 | 2025 | Monoferric |
| Vifor Pharma, INC. | $32.08 | 2022 | |
| Apellis Pharmaceuticals, INC. | $26.97 | 2025 | Empaveli |
| Chiesi USA, INC. | $26.40 | 2025 | Elfabrio |
| Novo Nordisk INC | $17.29 | 2025 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $14.91 | 2025 | Oxlumo |
| Mallinckrodt Enterprises LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.